© 2000 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
Recent Patterns and Predictors of Antipsychotic Medication Regimens Used To Treat Schizophrenia and Other Psychotic Disorders
Harvard Medical School Boston, MA, and a recipient of a Research Career Award from the National Institute of Mental Health (K01-MH0165-0l)
American Psychiatric Institute for Research and Education Washington, DC
Office of Research, American Psychiatric Association Washington, DC
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic Pittsburgh, PA, and Senior Scientist, RAND, Director, RAND-Pittsburgh Health Program Pittsburgh, PA
Send reprint requests to Dr. P.S. Wang, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave., Ste. 341, Boston, MA 02115; e-mail: pwang{at}rics.bwh.harvard.edu
Up-to-date data are needed on the types of treatments used by psychiatrists and the reasons for use of particular treatments. Using 1997 American Psychiatric Association (APA) Practice Research Network (PRN) Study data on patients with schizophrenia and other psychotic disorders, we identified the characteristics of antipsychotic medications (APMs) currently being prescribed and factors associated with the use of particular regimens. In this study population, use of the newer APMs, including risperidone, olanzapine, and clozapine, has increased rapidly and now accounts for over one-half of all APM use. Other intriguing findings include the fact that one-sixth of patients with schizophrenia and other psychotic disorders are concurrently treated with two or more APMs. Factors associated with being prescribed one of the newer APMs risperidone or otanzapine include being elderly, having more education, being white, having psychiatric comorbidity, and making fewer recent visits to a psychiatrist. The APA PRN Study data are an important new resource for mental health services researchers.
Keywords: Schizophrenia / psychotic disorders / antipsychotic medications / pharmacoepidemiology / psychiatrist prescribing patterns
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. S. Wang, C. M. Ulbricht, and M. Schoenbaum Improving Mental Health Treatments Through Comparative Effectiveness Research Health Aff., May 1, 2009; 28(3): 783 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Chaudhry, K. Neelam, V. Duddu, and N. Husain Ethnicity and psychopharmacology J Psychopharmacol, August 1, 2008; 22(6): 673 - 680. [Abstract] [PDF]
|
|
|
|
 |
|
 T. P. Gilmer, C. R. Dolder, D. P. Folsom, W. Mastin, and D. V. Jeste Antipsychotic Polypharmacy Trends Among Medi-Cal Beneficiaries With Schizophrenia in San Diego County, 1999-2004 Psychiatr Serv, July 1, 2007; 58(7): 1007 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Garver, A. Lazarus, K. Rajagopalan, L. Lamerato, L. M. Katz, L. S. Stern, M. Dolgitser, and J. J. Doyle Racial Differences in Medication Switching and Concomitant Prescriptions in the Treatment of Bipolar Disorder Psychiatr Serv, May 1, 2006; 57(5): 666 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herbeck, J. C. West, I. Ruditis, F. F. Duffy, D. J. Fitek, C. C. Bell, and L. R. Snowden Variations in Use of Second-Generation Antipsychotic Medication by Race Among Adult Psychiatric Patients Psychiatr Serv, June 1, 2004; 55(6): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Bond, H.-W. Kim, P. S. Meyer, P. J. Gibson, S. Tunis, J. D. Evans, P. Lysaker, M. L. McCoy, J. Dincin, and H. Xie Response to Vocational Rehabilitation During Treatment With First- or Second-Generation Antipsychotics Psychiatr Serv, January 1, 2004; 55(1): 59 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Partridge, J. Avorn, P. S. Wang, and E. P. Winer Adherence to Therapy With Oral Antineoplastic Agents J Natl Cancer Inst, May 1, 2002; 94(9): 652 - 661. [Abstract] [Full Text] [PDF]
|
|